Get the Stockscreener App
3.47
1.76%
0.06
After Hours:
3.31
-0.16
-4.61%
Aptevo Therapeutics Inc Stock (APVO) Latest News
Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World
FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World
Aptevo Therapeutics files $100M mixed securities shelf - MSN
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission RateCEO Interview Alert - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News Summary - Benzinga
Aptevo Therapeutics Inc. (APVO) reports earnings - Quartz
Aptevo Therapeutics Inc. SEC 10-K Report - TradingView
Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year - TipRanks
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - StockTitan
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - ACCESS Newswire
APVO stock plunges to 52-week low at $3.62 amid steep annual decline By Investing.com - Investing.com South Africa
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding - ACCESS Newswire
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale - ACCESS Newswire
Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline - TipRanks
TG Therapeutics (NASDAQ:TGTX) vs. Aptevo Therapeutics (NASDAQ:APVO) Head-To-Head Review - Defense World
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements - ACCESS Newswire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest - Defense World
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - ACCESS Newswire
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting - ACCESS Newswire
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - ACCESS Newswire
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion - ACCESS Newswire
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire
Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan
Trend Tracker for (APVO) - Stock Traders Daily
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
Aptevo reports full remission in AML trial By Investing.com - Investing.com UK
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - AccessWire
Aptevo's AML Drug Trial Hits 100% Remission Rate, Complete Cancer Cell Elimination in Phase 1b Study - StockTitan
(APVO) On The My Stocks Page - Stock Traders Daily
Aptevo Therapeutics executes reverse stock split - Investing.com India
Aptevo Therapeutics executes reverse stock split By Investing.com - Investing.com Australia
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - AccessWire
Aptevo's Novel Prostate Cancer Therapy Shows Promise in Preclinical Studies, Targets $24B Market - StockTitan
Sweden’s Alligator Makes Cuts To Avoid Extinction - News & Insights
Alligator Bioscience completes a rights issue of SEK 280 million - Marketscreener.com
Alligator Bioscience to make a rights issue of units of SEK 199 million - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
What's Going On With Aptevo Therapeutics Shares Friday? - Benzinga
Aptevo Therapeutics Announces 1-for-37 Reverse Stock Split - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split - Investing.com
Aptevo Therapeutics Announces 37-to-1 Reverse Split to Meet Nasdaq Requirements | APVO Stock News - StockTitan
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):